- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:02 | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement | 133 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| Mi | Lobe Sciences reports Q3 results | 1 | Seeking Alpha | ||
| Di | Lobe Sciences Ltd.: Lobe Sciences Reports Third Quarter 2026 Financial Results | 219 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic... ► Artikel lesen | |
| 13.08. | Lobe Sciences Ltd (2): Lobe Sciences arranges $2.1-million private placement | 1 | Stockwatch | ||
| 12.08. | Lobe Sciences to raise C$2.1M in private placement | 3 | Seeking Alpha | ||
| 12.08. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 546 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe"... ► Artikel lesen | |
| 05.08. | Lobe Sciences Ltd.: Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders | 278 | ACCESS Newswire | Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Lobe Sciences Ltd.... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.07. | Lobe Sciences Ltd (2): Lobe Sciences schedules AGSM for July 30 | 1 | Stockwatch | ||
| 07.07. | Lobe Sciences Ltd.: Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026 | 443 | ACCESS Newswire | The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with... ► Artikel lesen | |
| 09.06. | Lobe Sciences Ltd (2): Lobe Sciences settles $1.37M in mgmt, director fees | 3 | Stockwatch | ||
| 09.06. | Lobe Sciences Ltd.: Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares | 309 | ACCESS Newswire | Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholdersThe Canadian Securities Exchange has... ► Artikel lesen | |
| 02.06. | Lobe Sciences Ltd.: Lobe Sciences Announces Proposed Shares for Debt Transaction | 431 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 07.05. | Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York | 565 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential... ► Artikel lesen | |
| 06.05. | Lobe Sciences Ltd.: Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress | 312 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 24.04. | Lobe Sciences Ltd (2): Lobe Sciences cheers U.S. order for novel treatments | 4 | Stockwatch | ||
| 23.04. | Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders | 267 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing... ► Artikel lesen | |
| 21.04. | Lobe Sciences Ltd (2): Lobe Sciences hires Massive Intelligence for IR | 1 | Stockwatch | ||
| 21.04. | Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services | 343 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 20.04. | Lobe Sciences Ltd (2): Lobe Sciences closes $950,000 private placement | 2 | Stockwatch | ||
| 20.04. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update | 314 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,210 | 0,00 % | Abnehmboom 2.0! BioNxt Solutions, Novo Nordisk und Nestlé wachsen im Milliardenmarkt! | Die Abnehmspritze hat nicht nur den Pharmamarkt verändert, sondern wirkt sich auch sukzessive auf die Lebensmittelbranche aus. Der verschreibungspflichtige Wirkstoff Semaglutid zur Behandlung von Typ-2-Diabetes... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DXCM, ORKA, CON, ATAI | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen | |
| CYBIN | 10,120 | +0,40 % | Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board | Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,025 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,008 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Shares for Debt Settlement | TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip Nicotine Patent, Advancing RDT's Global Commercialization Strategy | Burlington, Ontario--(Newsfile Corp. - August 20, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in innovative... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 38,600 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| MODERNA | 124,60 | -16,72 % | Opening Bell: Moderna, Merck, Lowe's, Target, Walmart, Analog Devices | An den US-Börsen haben sich die Anleger am Dienstag zurückgehalten. Der Dow Jones fiel nach einem schwachen Start um 0,22 Prozent. Der Nasdaq Composite verlor 1,33 Prozent. Belastet wurde die Stimmung... ► Artikel lesen | |
| CG ONCOLOGY | 80,68 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,070 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| NURIX THERAPEUTICS | 27,790 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| BIONTECH | 93,10 | -3,82 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| APOGEE THERAPEUTICS | 134,72 | 0,00 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| TARSUS PHARMACEUTICALS | 73,44 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position | Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of... ► Artikel lesen |
Das Unternehmen LOBE SCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,039 Euro und damit +8,33 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.